WORLD PEPTIDEFOUNDATION
← Master Registry

Published peptide research references

Afamelanotide

Governed registry record

45 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.

Open the peptide evidence profile →

Approved source records

  1. 04111 Phlebotomy and afamelanotide as an efficient combined treatment of hepatoerythropoietic porphyria

    DOI: 10.1136/bmjgast-2024-icpp.15

    Source identity and connection checked by Codex (AI).

  2. 04121 Afamelanotide for the treatment of cutaneous phototoxicity of erythropoietic protoporphyria: the Scottish experience

    DOI: 10.1136/bmjgast-2024-icpp.33

    Source identity and connection checked by Codex (AI).

  3. 461 The effects of afamelanotide on UVR-induced DNA damage, acute inflammatory and DNA repair responses in human skin

    DOI: 10.1016/j.jid.2024.10.472

    Source identity and connection checked by Codex (AI).

  4. A Feasibility and Safety Study of Afamelanotide in Acute Stroke Patients – An Open Label, Proof of Concept, Phase Iia Clinical Trial

    DOI: 10.21203/rs.3.rs-2306958/v1

    Source identity and connection checked by Codex (AI).

  5. Afamelanotide Is Associated with Dose-Dependent Protective Effect from Liver Damage Related to Erythropoietic Protoporphyria.

    DOI: 10.3390/life13041066PMID: 37109595

    Source identity and connection checked by Codex (AI).

  6. Afamelanotide in managing cutaneous phototoxicity in erythropoietic protoporphyria: a Scottish perspective.

    DOI: 10.1093/ced/llaf306PMID: 40692281

    Source identity and connection checked by Codex (AI).

  7. Clinical Experience with Afamelanotide for the Protoporphyrias in the United States

    DOI: 10.1182/blood-2022-163566

    Source identity and connection checked by Codex (AI).

  8. Cryo-EM structure of afamelanotide-MC4R-Gs_Nb35 complex

    DOI: 10.2210/pdb7f54/pdb

    Source identity and connection checked by Codex (AI).

  9. EMA , It's Time to Reconsider! 10 Years Afamelanotide for Treating Erythropoietic Protoporphyria

    DOI: 10.1111/phpp.70039

    Source identity and connection checked by Codex (AI).

  10. From darkness to light: Case report on afamelanotide-treatment in a 9-year-old child with erythropoietic protoporphyria.

    DOI: 10.1016/j.jdcr.2025.11.022PMID: 41542313

    Source identity and connection checked by Codex (AI).

  11. PD03 Afamelanotide reduces the ultraviolet radiation erythemal response soon after application in healthy volunteers with skin phototypes II–III

    DOI: 10.1093/bjd/ljad113.341

    Source identity and connection checked by Codex (AI).

  12. PD05 The effects of afamelanotide on ultraviolet radiation-induced acute inflammatory and DNA repair responses in healthy human skin

    DOI: 10.1093/bjd/ljae090.169

    Source identity and connection checked by Codex (AI).

  13. Acute impact of afamelanotide on UVR erythemal and melanogenic responses in healthy humans in vivo: an exploratory study.

    2026

    DOI: 10.1007/s43630-026-00986-xPMID: 42678656

  14. Afamelanotide improves quality of life and light tolerance in Austrian erythropoietic protoporphyria patients.

    2026

    DOI: 10.1111/ddg.15996PMID: 41793078

  15. Investigation of the stability profile of therapeutic α-MSH analogue: Insights from liquid chromatography-high resolution mass spectrometry analysis of afamelanotide.

    2026

    DOI: 10.1016/j.jpba.2026.117362PMID: 41547183

  16. German Cohort Observational Study to Investigate the Short- and Long-Term Safety and Clinical Effectiveness of Afamelanotide 16 mg (SCENESSE) in Patients With Erythropoietic Protoporphyria (EPP).

    2025

    DOI: 10.1111/phpp.13012PMID: 40082741

  17. Afamelanotide for Treatment of the Protoporphyrias: Impact on Quality of Life and Laboratory Parameters in a US Cohort.

    2024

    DOI: 10.3390/life14060689PMID: 38929673

  18. Afamelanotide in protoporphyria and other skin diseases: a review.

    2024

    DOI: 10.5114/ada.2024.138818PMID: 38784937

  19. Erythropoietic protoporphyria and afamelanotide: a patient's perspective.

    2024

    DOI: 10.1093/ced/llad346PMID: 37831089

  20. The effects of cholecalciferol and afamelanotide on vitamin D levels in erythropoietic protoporphyria: a multicentre cohort study.

    2024

    DOI: 10.1093/bjd/ljae148PMID: 38634774

  21. Vitamin D status in patients with erythropoietic protoporphyria taking the systemic photoprotective agent afamelanotide.

    2024

    DOI: 10.1093/bjd/ljae191PMID: 38736212

  22. A feasibility and safety study of afamelanotide in acute stroke patients - an open label, proof of concept, phase iia clinical trial.

    2023

    DOI: 10.1186/s12883-023-03338-9PMID: 37496004

  23. Association of quality of life measures with afamelanotide treatment in patients with erythropoietic protoporphyria and x-linked protoporphyria: A retrospective cohort study.

    2023

    DOI: 10.1016/j.jaad.2022.10.012PMID: 36244556

  24. Erythropoietic protoporphyria in the Netherlands: Clinical features, psychosocial impact and the effect of afamelanotide.

    2023

    DOI: 10.1111/1346-8138.16690PMID: 36579412

  25. Into the Light: Afamelanotide and the Treatment of Erythropoietic Protoporphyria in the United States.

    2023

    DOI: 10.36849/jdd.7126PMID: 37683058

  26. Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria.

    2021

    DOI: 10.1080/17512433.2021.1879638PMID: 33507118

  27. Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications.

    2021

    DOI: 10.36849/jdd.5526PMID: 33683075

  28. Clinical and dermoscopic changes of acquired melanocytic nevi of patients treated with afamelanotide.

    2021

    DOI: 10.1007/s43630-021-00020-2PMID: 33721252

  29. Afamelanotide implants and narrow-band ultraviolet B phototherapy for the treatment of nonsegmental vitiligo in Asians.

    2020

    DOI: 10.1016/j.jaad.2020.01.035PMID: 31987791

  30. Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice.

    2020

    DOI: 10.1001/jamadermatol.2020.0352PMID: 32186677

  31. Increased phototoxic burn tolerance time and quality of life in patients with erythropoietic protoporphyria treated with afamelanotide - a three years observational study.

    2020

    DOI: 10.1186/s13023-020-01505-6PMID: 32811524

  32. [Medicaments and oral healthcare. Hyperpigmentation of oral soft tissues due to afamelanotide].

    2020

    DOI: 10.5177/ntvt.2020.04.19115PMID: 32459219

  33. Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders.

    2017

    DOI: 10.1007/s40262-016-0501-5PMID: 28063031

  34. Afamelanotide: A Review in Erythropoietic Protoporphyria.

    2016

    DOI: 10.1007/s40257-016-0184-6PMID: 26979527

  35. Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria.

    2015

    DOI: 10.1586/17512433.2014.956089PMID: 25470471

  36. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial.

    2015

    DOI: 10.1001/jamadermatol.2014.1875PMID: 25230094

  37. Afamelanotide for Erythropoietic Protoporphyria.

    2015

    DOI: 10.1056/nejmoa1411481PMID: 26132941

  38. Evaluation of the immunogenicity of the synthetic α-melanocyte-stimulating hormone (α-MSH) analogue afamelanotide ([Nle4-D-Phe7]-α-MSH, Scenesse®) in erythropoietic protoporphyria patients by ELISA detecting both anti-afamelanotide and anti-α-MSH antibodies.

    2015

    DOI: 10.1159/000362174PMID: 25402764

  39. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria.

    2015

    DOI: 10.1111/bjd.13598PMID: 25494545

  40. A bioassay for the detection of neutralizing antibodies against the α-melanocyte stimulating hormone analog afamelanotide in patients with erythropoietic protoporphyria.

    2013

    DOI: 10.1016/j.jpba.2012.11.040PMID: 23277150

  41. A review and update on melanocyte stimulating hormone therapy: afamelanotide.

    2013

    PMID: 23884489

  42. The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo.

    2013

    DOI: 10.1001/2013.jamadermatol.386PMID: 23407924

  43. Afamelanotide

    2012

    PMID: 38598652

  44. Pseudoleucoderma after injections of afamelanotide in a patient with atopic dermatitis.

    2011

    DOI: 10.2340/00015555-1062PMID: 21597671

  45. Afamelanotide, an agonistic analog of α-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria.

    2010

    DOI: 10.1517/13543784.2010.535515PMID: 21073357